-
Value Creation Report 2025
-
Eisai Releases Corporate Film “1 Percent, 1 Mission. Change the World.”
-
Human Capital Report 2024
-
September 24, 2025
LEQEMBI® (Lecanemab) Approved for the Treatment of Alzheimer’s Disease in Australia
-
September 24, 2025
Notice of the Settlement of Patent Infringement Litigation Related to Lenvatinib in the U.S.
-
September 17, 2025
Anti-MTBR (microtubule binding region) Tau Antibody Etalanetug Granted FDA Fast Track Designation
-
September 12, 2025
-
September 8, 2025
-
February 19, 2025
Eisai’s Corporate Pension Fund Announces Adoption of “Asset Owner Principles”
-
October 3, 2024
EISAI NAMED AS ONE OF NEWSWEEK’S WORLD’S MOST TRUSTWORTHY COMPANIES 2024
-
June 21, 2024
Notification Regarding Revision of “Eisai Global Code of Conduct for Business Partners”
-
June 3, 2024
The Naito Museum of Pharmaceutical Science and Industry Listed as “Registered Museum”
-
April 8, 2024
Sustainability
32 countries 2.53billion tablets
Number of countries supplied with lymphatic filariasis treatment
and volume supplied (as of June 2025)
Eisai is promoting initiatives for improving access to medicines to contribute to people in developing and emerging countries
